Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 11, 2026, 11:04 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 537 matching trials from the live ClinicalTrials.gov search.
Conditions
Coronary Artery Disease, Cerebral Vascular Disease, Peripheral Artery Disease, Renal Insufficiency, Diabetes, COPD, Hypertension, Active Smoker, Cancer, CHF, Prior DVT/PE
Interventions
Not listed
Lead sponsor
NYU Langone Health
Other
Eligibility
21 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2020
U.S. locations
1
States / cities
New York, New York
Conditions
Gestational Diabetes, Pregestational Diabetes
Interventions
Completion of Glucose logs
Behavioral
Lead sponsor
University of Rochester
Other
Eligibility
18 Years to 60 Years · Female only
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Rochester, New York
Conditions
Vasopressin Deficiency
Interventions
Intranasal Oxytocin (IN-OXT), Placebo
Drug
Lead sponsor
Elizabeth Austen Lawson
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Completed Phase 3 Interventional Results available

Effect of Sulodexide in Early Diabetic Nephropathy

NCT00130208
Conditions
Diabetic Nephropathy
Interventions
Sulodexide, Placebo
Drug
Lead sponsor
Keryx Biopharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
1,056 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Chicago, Illinois
Completed Not applicable Interventional Accepts healthy volunteers Results available

Metformin Compared to Glyburide in Gestational Diabetes

NCT00965991
Conditions
Gestational Diabetes
Interventions
metformin, Glyburide
Drug
Lead sponsor
University of New Mexico
Other
Eligibility
13 Years and older · Female only
Enrollment
149 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2023
U.S. locations
1
States / cities
Albuquerque, New Mexico
Conditions
Gestational Diabetes
Interventions
Group 1: one-hour GCT, Group 2: CGM placement
Device
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years and older · Female only
Enrollment
1,628 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Houston, Texas
Conditions
Heart Failure, Chronic Kidney Diseases, Diabetes Mellitus, Type 2
Interventions
Medically tailored meals
Other
Lead sponsor
Kaiser Permanente
Other
Eligibility
18 Years and older
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
5
States / cities
Oakland, California • San Francisco, California • San Rafael, California + 2 more
Conditions
Chronic Kidney Disease, Diabetic Nephropathy
Interventions
Placebo for Atrasentan 0.2 mg/mL solution, 0.25 mg Atrasentan QD, 0.75 mg Atrasentan QD, 1.75 mg Atrasentan QD
Drug
Lead sponsor
AbbVie (prior sponsor, Abbott)
Industry
Eligibility
18 Years and older
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
24
States / cities
Tempe, Arizona • Azusa, California • Los Angeles, California + 16 more
Active, not recruiting No phase listed Observational

Prospective Decision Impact Trial of KidneyIntelX

NCT04960514
Conditions
Diabetic Kidney Disease, Chronic Kidney Disease Stage 1, Chronic Kidney Disease Stage 2, Chronic Kidney Disease, Stage 3 (Moderate)
Interventions
KidneyIntelX
Diagnostic Test
Lead sponsor
Renalytix AI, Inc.
Industry
Eligibility
23 Years and older
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Active, not recruiting Phase 4 Interventional

Pentoxifylline in Diabetic Kidney Disease

NCT03625648
Conditions
Diabetic Kidney Disease
Interventions
Pentoxifylline, Placebo
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
2,376 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2030
U.S. locations
34
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Loma Linda, California + 31 more
Conditions
Diabetic Nephropathy
Interventions
LY333531
Drug
Lead sponsor
Chromaderm, Inc.
Industry
Eligibility
30 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2004
U.S. locations
15
States / cities
La Jolla, California • Walnut Creek, California • Jacksonville, Florida + 12 more
Conditions
Type 2 Diabetes, Chronic Kidney Diseases
Interventions
Oral sodium suppression test, Saline suppression test, Captopril suppression test, Dexamethasone suppression test, Cosyntropin stimulation test
Diagnostic Test
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 80 Years
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Chronic Kidney Disease, Type 2 Diabetes
Interventions
Finerenone (Kerendia, BAY94-8862), Sodium-glucose cotransporter-2 inhibitors (SGLT2i)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
17,847 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Whippany, New Jersey
Conditions
Renal Insufficiency, Chronic, Diabetes Mellitus, Type 2
Interventions
Bardoxolone methyl (amorphous dispersion)
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years and older
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
26
States / cities
Montgomery, Alabama • Phoenix, Arizona • Tempe, Arizona + 23 more
Conditions
Diabetic Kidney Disease (DKD)
Interventions
CSL346, Placebo
Biological · Drug
Lead sponsor
CSL Behring
Industry
Eligibility
25 Years and older
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
22
States / cities
Covina, California • Fresno, California • Lomita, California + 15 more
Conditions
Gestational Diabetes Mellitus
Interventions
BABI-2 Lifestyle Intervention
Behavioral
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older · Female only
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Denver, Colorado
Conditions
Diabetic Nephropathy
Interventions
Sulodexide, Placebo
Drug
Lead sponsor
Keryx Biopharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
968 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Chicago, Illinois
Completed Not applicable Interventional Results available

Postpartum Weight Loss for Women at Elevated Cardiovascular Risk

NCT04914819
Conditions
Weight Loss, Postpartum Weight Retention, Hypertension in Pregnancy, Diabetes Mellitus in Pregnancy, Preeclampsia, Recruitment
Interventions
Online Behavioral Weight Loss Program, Virtual weigh-in
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older · Female only
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Pregestational Diabetes, Pregnancy
Interventions
Use of insulin glargine once daily, Use of insulin glargine twice daily
Drug
Lead sponsor
Eastern Virginia Medical School
Other
Eligibility
18 Years and older · Female only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Norfolk, Virginia
Completed No phase listed Observational

Glucose Frequent of A1GDM in Labor

NCT06744621
Conditions
Gestational Diabetes, Controlled by Diet
Interventions
Fingerstick
Other
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years to 51 Years · Female only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
New York, New York
Conditions
Septic Shock
Interventions
Not listed
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Cleveland, Ohio
Conditions
Chronic Kidney Disease (Stages 4 and 5), Kidney Disease, Type 2 Diabetes
Interventions
Physiologic Insulin Resensitization (PIR)
Other
Lead sponsor
Well Cell Global
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
2
States / cities
Phoenix, Arizona • Scottsdale, Arizona
Conditions
Type 2 Diabetes Mellitus, Diabetes Mellitus, Type 2, Renal Insufficiency
Interventions
GSK189075
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 75 Years
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
4
States / cities
Orlando, Florida • Minneapolis, Minnesota • Knoxville, Tennessee + 1 more
Conditions
Chronic Kidney Disease, Type 2 Diabetes Mellitus, Heart Failure
Interventions
sMRA therapies
Other
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Whippany, New Jersey